Press Releases CombiGene AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 10:23:37 2024-04-29 am EDT			5-day change	1st Jan Change
3.75 ^SEK	-0.53%		+0.81%	+39.41%

Mar. 13	CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	CI
Feb. 21	Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	CI

CombiGene AB (publ) publishes annual report for 2023	Apr. 26	AQ
Notice of Annual General Meeting in CombiGene AB (publ)	Apr. 18	AQ
BioStock: CombiGene's CEO comments on the patent approvals in Australia and India	Mar. 20	AQ
CombiGene’s epilepsy project CG01 has been granted patent in two new countries	Mar. 13	AQ
BioStock: Comments from Orphazyme on the investment in CombiGene	Mar. 04	AQ
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	Feb. 21	AQ
Year-end report January-December 2023 CombiGene AB (Publ)	Feb. 16	AQ
BioStock: CombiGene comments on the discontinued CGT2 project	Feb. 02	AQ
CombiGene discontinues the preclinical development of the lipodystrophy project CGT2	Feb. 01	AQ
CombiGene: "We continue to believe in the epilepsy project CG01"	Jan. 16	AQ
CombiGene has regained the global rights to the epilepsy project CG01	Jan. 13	AQ
BioStock: CombiGene comments on Eurostars funding	Dec. 22	AQ
Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project	Dec. 20	AQ
New issue of CombiGenes, no 5 2023	Nov. 27	AQ
BioStock: CombiGene focuses on the pain project	Nov. 15	AQ
Interim report January – September 2023 for CombiGene AB (publ)	Nov. 10	AQ
BioStock: CombiGene has chosen CRO for the pain project	Nov. 01	AQ
CombiGene chooses Charles River as preclinical toxicology partner for COZY01 pain project	23-10-31	AQ
CombiGene and Zyneyro choose initial indication in the COZY01 pain project	23-10-26	AQ
CombiGene AB (publ): Nominating committee	23-10-25	AQ

No results for this search